Reported 2,834,643 shares, unchanged from the prior quarter.
Reported value 16.7%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2024-06-30 | 52618090 |
| 2024-09-30 | 70429892 |
| 2024-12-31 | 55746429 |
| 2025-03-31 | 62594954 |
| 2025-06-30 | 78158591 |
| 2025-09-30 | 109681897 |
| 2025-12-31 | 116582648 |
| 2026-03-31 | 136083745 |
| 2026-06-30 | 181275420 |
| 2026-09-30 | 211492714 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 2,834,643 | 0 (0.0%) | 1.0% | $211,492,714 | 2026-11-16 | |
| Q2 2026 | Added | 2,834,643 | +8,397 (0.3%) | 0.91% | $181,275,420 | 2026-08-14 | |
| Q1 2026 | Unchanged | 2,826,246 | 0 (0.0%) | 0.78% | $136,083,745 | 2026-05-15 | |
| Q4 2025 | Added | 2,826,246 | +1,577 (0.1%) | 0.68% | $116,582,648 | 2026-02-17 | |
| Q3 2025 | Unchanged | 2,824,669 | 0 (0.0%) | 0.79% | $109,681,897 | 2025-11-14 | |
| Q2 2025 | Added | 2,824,669 | +6,346 (0.2%) | 0.76% | $78,158,591 | 2025-08-14 | |
| Q1 2025 | Unchanged | 2,818,323 | 0 (0.0%) | 0.69% | $62,594,954 | 2025-05-15 | |
| Q4 2024 | Unchanged | 2,818,323 | 0 (0.0%) | 0.6% | $55,746,429 | 2025-02-14 | |
| Q3 2024 | Unchanged | 2,818,323 | 0 (0.0%) | 0.73% | $70,429,892 | 2024-11-14 | |
| Q2 2024 | New | 2,818,323 | +2,818,323 (0.0%) | 0.67% | $52,618,090 | 2024-08-14 |
Who else reported the position
328 managers reported KINIKSA PHARMACEUTICALS INTL for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 7,487,391 | +516,030 | 0.02% | $558,634,260 | 10 qtrs |
| BlackRock Inc | Added | 2,943,674 | +204,059 | < 0.01% | $219,627,516 | 9 qtrs |
| BAKER BROS ADVISORS LP This report | Unchanged | 2,834,643 | 0 | 1.0% | $211,492,714 | 10 qtrs |
| Rubric Capital Management LP | Reduced | 2,813,469 | -1,186,331 | 1.97% | $209,912,922 | 10 qtrs |
| TANG CAPITAL MANAGEMENT LLC | Unchanged | 2,259,889 | 0 | 7.76% | $168,610,318 | 10 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Added | 2,030,666 | +119,331 | < 0.01% | $151,507,990 | 3 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 1,433,679 | +72,839 | < 0.01% | $106,966,790 | 3 qtrs |
| ARROWSTREET CAPITAL LIMITED PARTNERSHIP | Added | 1,093,930 | +136,416 | 0.03% | $81,618,117 | 10 qtrs |
| MORGAN STANLEY | Reduced | 936,373 | -74,770 | < 0.01% | $69,862,871 | 10 qtrs |
| STATE STREET CORPORATION | Added | 926,267 | +222,073 | < 0.01% | $69,108,781 | 10 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- ORD SHS CL A
Voting authority reported
- Sole
- 2,834,643
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.